Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy (Q33837881)

29 July 2017

Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy (English)

1 reference

29 July 2017

1 reference

Lilach M Friedman

1

1 reference

29 July 2017

Ariel Rinon

2

1 reference

29 July 2017

Bilha Schechter

3

1 reference

29 July 2017

Ljuba Lyass

4

1 reference

29 July 2017

Sara Lavi

5

1 reference

29 July 2017

Sarah S Bacus

6

1 reference

29 July 2017

Michael Sela

7

1 reference

29 July 2017

Yosef Yarden

8

1 reference

29 July 2017

language of work or name

English

0 references

publication date

31 January 2005

1 reference

Proceedings of the National Academy of Sciences of the United States of America

29 July 2017

1 reference

29 July 2017

102

1 reference

29 July 2017

6

1 reference

29 July 2017

1915-1920

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Untangling the ErbB signalling network

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Induction of mutant dynamin specifically blocks endocytic coated vesicle formation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Humanization of an anti-p185HER2 antibody for human cancer therapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

28 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.0409610102

Two pathways for serum regulation of the c-fos serum response element require specific sequence elements and a minimal domain of serum response factor

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.0409610102

Second cysteine-rich region of epidermal growth factor receptor contains targeting information for caveolae/rafts

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.0409610102

Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=548578

Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15684082

12 December 2020

inferred from PubMed ID database lookup

A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15684082

12 December 2020

inferred from PubMed ID database lookup

Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15684082

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1073/PNAS.0409610102

1 reference

release_spvq4vdy2nbqvnsoyva7hdr2ji

29 July 2017

0 references

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/spvq4vdy2nbqvnsoyva7hdr2ji

24 November 2022

mapped directly with Wikidata item

PMCID

548578

1 reference

29 July 2017

1 reference